Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 537-544

  Amparo, Francisco ^a   Sadrai, Zahra ^a   Jin, Yiping ^a   Alfonso Bartolozzi, Belen ^a   Wang, Haobing ^a   Shikari, Hasanain ^a   Ciolino, Joseph B ^a   Chodosh, James ^a   Jurkunas, Ula ^a   Schaumberg, Debra A ^b   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; BLURRED VISION; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; CORNEAL PACHYMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CORNEAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874715016     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11032     Document Type: Article

References (39)

1. Chang, Gabison E, Kato T, Azar D. Corneal neovascularization. Curr Opin Ophthamol. 2001;12:242-249.
2. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257.
3. Hajrasouliha AR, Funaki T, Sadrai Z, Hattori T, Chauhan SK, Dana R. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2012;53: 1244-1250.
4. Niederkorn J. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191-226.
5. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
6. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
7. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126:71-77.
8. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
9. Nehls V, Denzer K, Drenckhahn D. Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res. 1992;270:469-474.
10. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy. 2005;4:3-8.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine. 1995;1:27-31.
12. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
13. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in woundand inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
14. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000; 41:2514-2522.
15. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
16. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:2411-2417.
17. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRh+ perivascular progenitor cells in tumours regulates pericyte differentiation and vascular survival. Nat Cell Biol. 2005;7: 870-879.
18. Finkenzeller B, Technau A, Marme D. Platelet-derived growth factor induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Biochem Biophys Res Commun. 1995;208:432-439.
19. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003;112:1142-1151.
20. Lindblom P, Gerhardt H, Liebner S, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17:1835-1840.
21. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest. 2003;112:1134-1136.
22. Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121:2606-2614.
23. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
24. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111:1287-1295.
25. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003;162:183-193.
26. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med. 2010;207:491-503.
27. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036-2053.
28. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[4-[(2, 3-dimethyl-2Hindazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51:4632-4640.
29. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamics correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6:2012-2021.
30. Food and Drug Administration. FDA labeling information. FDA website. [online]. Available at: http://www.accessdata.fda. gov/drugsatfda_docs/label/2009/022465lbl.pdf. Accessed June 19, 2012.
31. van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib in metastatic soft tissue sarcoma (PALETTE): a randomized, double-blind, placebo controlled phase 3 trial. Lancet. 2012; 379:1879-1886.
32. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009;127:494-499.
33. Yafai Y, Yang XM, Niemeyer M, et al. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol. 2011;666:12-18.
34. Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011;82:346-50.
35. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127:381-9.
36. Wang S, Li X, Parra M, Verdin E, Bassel-Duby R, Olson EN. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A. 2008;105:7738-7743.
37. Cursiefen C, Hofmann-Rummelt C, Küchle M, Schlötzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol. 2003;87:101-106.
38. Chaoran Z, Zhirong L, Gezhi X. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2011;249:1493-1501.
39. Nieto M, Borregaard J, Ersbøll J, et al. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the committee for Medicinal Products for Human Use. Clin Cancer Res. 2011;17:6608-6614.